GSK moves bioprocessing to UK from India

A focus on efficiency at a GlaxoSmithKline manufacturing plant in the UK has caught the eye of CEO Andrew Witty and prompted him to take an unusual action. He's moving biomanufacturing from India to the drug giant's facilities in Montrose, a town within Scotland's Angus region.

Witty acknowledged the cost and process-efficiency improvements at Montrose, which currently employs 280. "This is a workforce that has rolled with the punches," he says, as quoted in The Courier. The ops team "outmaneuvered" a plant closure, which appeared imminent a few years ago.

Steroid manufacturing is one operation that will return to the town. Locals are hoping that Montrose may become the chosen location for a new biopharma plant being planned by the drug giant.

- here's the story

Suggested Articles

The FDA is bracing for drug and medical supply shortages in the U.S. as the COVID-19 outbreak from China continues to spread globally.

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.

Branded drug sales in China could suffer in the short term as marketing activities for new meds are limited to reduce the risk of contagion.